Inhibition of DYRK1A and GSK3B induces human β-cell proliferation

Nature Communications

Volumn 6, Issue , 2015, Pages

  Shen, Weijun ^a,c   Taylor, Brandon ^a   Jin, Qihui ^a   Nguyen Tran, Van ^a   Meeusen, Shelly ^a   Zhang, You Qing ^a   Kamireddy, Anwesh ^a   Swafford, Austin ^a   Powers, Andrew F ^a   Walker, John ^a   Lamb, John ^a   Bursalaya, Badry ^a   Didonato, Michael ^a   Harb, George ^a   Qiu, Minhua ^a   Filippi, Christophe M ^a   Deaton, Lisa ^a   Turk, Carolina N ^a   Suarez Pinzon, Wilma L ^b   Liu, Yahu ^a   Hao, Xueshi ^a   Mo, Tingting ^a   Yan, Shanshan ^a   Li, Jing ^a   Herman, Ann E ^a,d   Hering, Bernhard J ^b   Wu, Tom ^a   Martin Seidel, H ^a,e   McNamara, Peter ^a   Glynne, Richard ^a   Laffitte, Bryan ^a   more..

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c California Institute for Biomedical Research   (United States)

^d GENENTECH INC   (United States)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL COMPOSITION; CELLS AND CELL COMPONENTS; DIABETES; DRUG DEVELOPMENT; ENZYME ACTIVITY; PROTEIN; RODENT;

MUS;

AMINOPYRIDAZINE; DYRK KINASE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; GSK3B PROTEIN, HUMAN; GSK3B PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PYRIDAZINE DERIVATIVE;

ANIMAL; CELL DIVISION; CELL PROLIFERATION; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; DOWN REGULATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; CELL DIVISION; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; INSULIN-SECRETING CELLS; MALE; MICE; MICE, TRANSGENIC; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRIDAZINES;

EID: 84945263728     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9372     Document Type: Article

References (50)

1. Matveyenko, A. V., Butler, P. C. Relationship between beta-cell mass and diabetes onset. Diabetes Obes. Metab. 10(Suppl 4): 23-31 (2008).
2. Butler, A. E. et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110 (2003).
3. Stumvoll, M., Goldstein, B. J., van Haeften, T. W. Type 2 diabetes: pathogenesis and treatment. Lancet 371, 2153-2156 (2008).
4. Schafer, S. A., Machicao, F., Fritsche, A., Haring, H. U., Kantartzis, K. New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms. Diabetes Res. Clin. Pract. 93(Suppl 1): S9-S24 (2011).
5. Dor, Y., Brown, J., Martinez, O. I., Melton, D. A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429, 41-46 (2004).
6. Teta, M., Rankin, M. M., Long, S. Y., Stein, G. M., Kushner, J. A. Growth and regeneration of adult beta cells does not involve specialized progenitors. Dev. Cell 12, 817-826 (2007).
7. Meier, J. J. et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 57, 1584-1594 (2008).
8. Cozar-Castellano, I. et al. Evaluation of beta-cell replication in mice transgenic for hepatocyte growth factor and placental lactogen: comprehensive characterization of the G1/S regulatory proteins reveals unique involvement of p21cip. Diabetes 55, 70-77 (2006).
9. Fiaschi-Taesch, N. et al. Survey of the human pancreatic beta-cell G1/S proteome reveals a potential therapeutic role for cdk-6 and cyclin D1 in enhancing human beta-cell replication and function in vivo. Diabetes 58, 882-893 (2009).
10. Fiaschi-Taesch, N. M. et al. Cytoplasmic-nuclear trafficking of G1/S cell cycle molecules and adult human beta-cell replication: a revised model of human beta-cell G1/S control. Diabetes 62, 2460-2470 (2013).
11. Fiaschi-Taesch, N. M. et al. Induction of human beta-cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6. Diabetes 59, 1926-1936 (2010).
12. Guthalu Kondegowda, N. et al. Parathyroid hormone-related protein enhances human ss-cell proliferation and function with associated induction of cyclin-dependent kinase 2 and cyclin E expression. Diabetes 59, 3131-3138 (2010).
13. Parnaud, G. et al. Proliferation of sorted human and rat beta cells. Diabetologia 51, 91-100 (2008).
14. Porat, S. et al. Control of pancreatic beta cell regeneration by glucose metabolism. Cell Metab. 13, 440-449 (2011).
15. Rutti, S. et al. In vitro proliferation of adult human beta-cells. PloS ONE 7, e35801 (2012).
16. Yi, P., Park, J. S., Melton, D. A. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell 153, 747-758 (2013).
17. Wang, P. et al. A high-throughput chemical screen reveals that harminemediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat. Med. 21, 383-388 (2015).
18. Stewart, A. F. Betatrophin versus bitter-trophin and the elephant in the room: time for a new normal in beta-cell regeneration research. Diabetes 63, 1198-1199 (2014).
19. Shen, W. et al. Small-molecule inducer of beta cell proliferation identified by high-throughput screening. J. Am. Chem. Soc. 135, 1669-1672 (2013).
20. Rieck, S. et al. Overexpression of hepatocyte nuclear factor-4alpha initiates cell cycle entry, but is not sufficient to promote beta-cell expansion in human islets. Mol. Endocrinol. 26, 1590-1602 (2012).
21. Shrivastav, M., De Haro, L. P., Nickoloff, J. A. Regulation of DNA double-strand break repair pathway choice. Cell Res. 18, 134-147 (2008).
22. Gupta, A. et al. Role of 53BP1 in the regulation of DNA double-strand break repair pathway choice. Radiat. Res. 181, 1-8 (2014).
23. Nir, T., Melton, D. A., Dor, Y. Recovery from diabetes in mice by beta cell regeneration. J. Clin. Invest. 117, 2553-2561 (2007).
24. Berg, S. et al. Discovery of novel potent and highly selective glycogen synthase kinase-3beta (GSK3beta) inhibitors for Alzheimer's disease: design, synthesis, characterization of pyrazines. J. Med. Chem. 55, 9107-9119 (2012).
25. Liu, H. et al. Glycogen synthase kinase-3 and mammalian target of rapamycin pathways contribute to DNA synthesis, cell cycle progression, proliferation in human islets. Diabetes 58, 663-672 (2009).
26. Liu, Y. et al. Conditional ablation of Gsk-3beta in islet beta cells results in expanded mass and resistance to fat feeding-induced diabetes in mice. Diabetologia 53, 2600-2610 (2010).
27. Liu, Z., Tanabe, K., Bernal-Mizrachi, E., Permutt, M. A. Mice with beta cell overexpression of glycogen synthase kinase-3beta have reduced beta cell mass and proliferation. Diabetologia 51, 623-631 (2008).
28. Mussmann, R. et al. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J. Biol. Chem. 282, 12030-12037 (2007).
29. MacAulay, K. et al. Constitutive activation of GSK3 down-regulates glycogen synthase abundance and glycogen deposition in rat skeletal muscle cells. J. Biol. Chem. 280, 9509-9518 (2005).
30. Pansters, N. A. et al. Segregation of myoblast fusion and muscle-specific gene expression by distinct ligand-dependent inactivation of GSK-3beta. Cell. Mol. Life Sci. 68, 523-535 (2011).
31. Cohen, P., Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 3, 479-487 (2004).
32. Keefe, M. D. et al. beta-catenin is selectively required for the expansion and regeneration of mature pancreatic acinar cells in mice. Dis. Models Mech. 5, 503-514 (2012).
33. Arron, J. R. et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595-600 (2006).
34. Goodyer, W. R. et al. Neonatal beta cell development in mice and humans is regulated by calcineurin/NFAT. Dev. Cell 23, 21-34 (2012).
35. Heit, J. J. et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 443, 345-349 (2006).
36. Kelly, P. A., Rahmani, Z. DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, MEK1. Mol. Biol. Cell 16, 3562-3573 (2005).
37. Becker, W., Sippl, W. Activation, regulation, inhibition of DYRK1A. FEBS. J. 278, 246-256 (2011).
38. Beals, C. R., Sheridan, C. M., Turck, C. W., Gardner, P., Crabtree, G. R. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275, 1930-1934 (1997).
39. Gwack, Y. et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 441, 646-650 (2006).
40. Wu, H., Peisley, A., Graef, I. A., Crabtree, G. R. NFAT signaling and the invention of vertebrates. Trends Cell Biol. 17, 251-260 (2007).
41. Weir, M. R., Fink, J. C. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am. J. Kidney Dis. 34, 1-13 (1999).
42. Chen, J. Y., Lin, J. R., Tsai, F. C., Meyer, T. Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle. Mol. Cell 52, 87-100 (2013).
43. Litovchick, L., Florens, L. A., Swanson, S. K., Washburn, M. P., DeCaprio, J. A. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev. 25, 801-813 (2011).
44. Rachdi, L. et al. Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass. Diabetologia 57, 960-969 (2014).
45. Aitken, R. J. et al. Early-onset, coexisting autoimmunity and decreased HLA-mediated susceptibility are the characteristics of diabetes in Down syndrome. Diabetes Care 36, 1181-1185 (2013).
46. Bergholdt, R., Eising, S., Nerup, J., Pociot, F. Increased prevalence of Down's syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study. Diabetologia 49, 1179-1182 (2006).
47. O'Roak, B. J. et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 338, 1619-1622 (2012).
48. van Bon, B. W. et al. Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. Mol. Psychiatry 1-7. doi:10. 1038/mp. 2015. 5 (2015).
49. Milo-Landesman, D. et al. Correction of hyperglycemia in diabetic mice transplanted with reversibly immortalized pancreatic beta cells controlled by the tet-on regulatory system. Cell Transplant. 10, 645-650 (2001).
50. Huang da, W., Sherman, B. T., Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).